Introduction
============

Acute myeloid leukemia (AML), a clonal oncohematological disorder, is characterized by disrupted maturation and programmed cell death (apoptosis), accompanied by uncontrolled proliferation of immature hematopoietic progenitor cells and subsequent suppression of functionally normal hematopoiesis.[@b1-ott-10-4143],[@b2-ott-10-4143] Recent advances in genetics have greatly improved our understanding of the molecular mechanisms underlying leukemic transformation.[@b3-ott-10-4143],[@b4-ott-10-4143] DNA methylation of CpG islands within gene promoter regions, the most extensively and systematically studied epigenetic mechanism, is crucial for gene regulation during normal hematological cell development.[@b5-ott-10-4143] Hypermethylation within the promoters of anti-oncogenes appears to be especially common in some or all types of human hematopoietic neoplasms.[@b6-ott-10-4143]--[@b8-ott-10-4143] To date, many genes have been shown to contribute to leukemogenesis via epigenetic silencing. Our previous reports indicated aberrant hypermethylation of *CTNNA1*, *CHFR1*, and miR-193a in several myeloid malignancies.[@b9-ott-10-4143]--[@b11-ott-10-4143]

*RASSF1A*, considered an important tumor suppressor gene, is located on chromosome 3p21.[@b12-ott-10-4143] *RASSF1A* represents potential Ras effectors and plays vital biological roles in cancer progression.[@b13-ott-10-4143] Several studies have shown that *RASSF1A* is expressed in normal tissues, including hematopoietic cells; however, its expression is significantly lower in human cancer.[@b14-ott-10-4143]

The current study aimed to assess the methylation levels of the *RASSF1A* promoter by quantitative methylation-specific polymerase chain reaction (qMS-PCR) in bone marrow (BM) biopsy specimens from non-M3 AML patients. The overarching objective was to identify a subset of patients who might harbor aberrant methylation levels, and in a complementary approach, to comparatively examine the clinical characteristics of these patients. In addition, chromosomal abnormalities and gene mutations known to be associated with AML were assessed for their associations with *RASSF1A* hypermethylation. Furthermore, to predict the clinical impact of our findings, we evaluated relapse-free survival (RFS) and overall survival (OS) in relation to *RASSF1A* methylation levels in the study population.

Materials and methods
=====================

Patients
--------

This study included 226 newly diagnosed patients with non-M3 AML visiting the Chinese PLA General Hospital and China-Japan Friendship Hospital, from July 2006 to March 2015, and 30 healthy controls. Written informed consent was obtained from each subject for sample preservation and genetic assays. The study was approved by the ethics committees of the Chinese PLA General Hospital and China-Japan Friendship Hospital. BM samples were collected during routine clinical examination, and those with more than 50% blastocysts, identified by morphologic assessment, were selected. The clinical characteristics of patients are described in [Table 1](#t1-ott-10-4143){ref-type="table"}. All patients with non-M3 AML received intensive induction therapy with high-dose cytarabine-based regimens or monotherapy with decitabine (demethylating treatment) followed by consolidation therapy. Twenty-nine patients underwent allogeneic hematopoietic stem cell transplantation, and 26 received autologous hematopoietic stem cell transplantation.

Clinical end points
-------------------

Complete remission (CR) was defined as no anemia, bleeding, infection, leukemic cell infiltration, circulating leukemic blastocysts, or evidence of extramedullary leukemia, with a recovery of morphologically normal BM and blood cell amounts. In addition, BM cells and primitive promyelocytic-stage cells (or immature cells) were \<5%, with normal erythroid--megakaryocyte system. Relapse was defined as ≥5% BM blastocysts, circulating leukemic blastocysts, or the emergence of extramedullary leukemic cells. OS was determined from leukemia diagnosis to death, censoring patients alive at the last follow-up. RFS was determined from the date of CR to relapse or death from any cause, censoring patients alive at the last follow-up.

DNA isolation, bisulfite modification, and qMS-PCR
--------------------------------------------------

Genomic DNA was extracted and purified from BM specimens with Genomic DNA Purification Kit (Promega, Madison, WI, USA). Then, 1 μg of genomic DNA was treated with sodium bisulfate using EpiTect Kit (Qiagen, Hilden, Germany). Bisulfite-treated DNA was amplified by qMS-PCR using primers and probes specific for *RASSF1A* and *MYOD1* (reference gene) (shown in [Table S1](#SD1-ott-10-4143){ref-type="supplementary-material"}). Polymerase chain reaction (PCR) was carried out in a 40 μL volume with 20 μL MethyLight Master Mix (Qiagen), 0.25 μM of each primer, *RASSF1A* or *MYOD1* gene probes, and 20 ng bisulfite-treated DNA. PCR conditions consisted of an initial denaturation step of 95°C for 5 minutes, followed by 40 cycles of denaturation for 15 seconds at 95°C and annealing for 60 seconds at 61°C. Standard curves were established for *RASSF1A* and *MYOD1* using 10-fold serial dilutions of five different plasmid concentrations. Relative methylation levels of *RASSF1A* were calculated by the ratio of *RASSF1A* copies to that of *MYOD1*.

Karyotype analysis and fluorescence in situ hybridization (FISH)
----------------------------------------------------------------

A total of 226 patients were submitted to cytogenetic analysis of BM samples at diagnosis by the direct method or 24-hour culture. The cytogenetic assays were performed independently by at least two cytogenetic technicians or pathologists. Metaphase chromosomes were assessed by G-banding, with chromosomal abnormalities presented according to the International System for Human Cytogenetic Nomenclature.[@b15-ott-10-4143] Simultaneous presentation of at least three unrelated cytogenetic abnormalities in one clone was defined as complex cytogenetic abnormalities. Cytogenetic abnormalities were divided into favorable, intermediate, and unfavorable karyotype groups, based on published criteria accepted by the Southwest Oncology Group (SWOG).[@b16-ott-10-4143] Besides, −5/5q-, −7/7q-, inv(16)/t(16;16), and 11q23 rearrangement abnormalities were confirmed by FISH.

Real-time quantitative polymerase chain reaction (RT-qPCR)
----------------------------------------------------------

Total RNA was isolated from BM samples from patients with non-M3 AML at diagnosis, with the Qiazol isolation reagent (Qiagen). Then, cDNA was obtained using a reverse transcription kit (Promega). Quantification of *RASSF1A* and *ABL1* transcripts was performed by RT-qPCR with specific primers and probes ([Table S2](#SD2-ott-10-4143){ref-type="supplementary-material"}). The PCR volume was 40 μL, including 20 μL TaqMan Universal Master Mix (Life Technologies), 0.25 μM of each primer, *RASSF1A* and *ABL1* gene probes, and 20 ng cDNA. The PCR program comprised 40 cycles of denaturation for 15 seconds at 95°C and annealing for 60 seconds at 60°C. Standard curves were generated for the *RASSF1A* and *ABL1* genes by 10-fold serial dilutions of five different plasmid concentrations. Relative expression of *RASSF1A* was determined as the ratio of *RASSF1A* copies to that of *ABL1*.

Detection of gene mutations
---------------------------

To assess the associations of gene mutations occurring in AML patients with the methylation status of the *RASSF1A* promoter region, DNA sequencing was conducted to detect *NPM1*, *FLT3-ITD*, *ASXL1*, *IDH1*, *DNMT3A*, *RUNX1*, *U2AF1*, *TET2*, *SRSF2*, *NRAS*, *CEBPA*, *KIT*, and *SF3B1* with hyperfrequency-mutation sequences, as previously reported.[@b9-ott-10-4143],[@b10-ott-10-4143],[@b17-ott-10-4143]--[@b22-ott-10-4143] The primers used for sequencing are shown in [Table S3](#SD3-ott-10-4143){ref-type="supplementary-material"}.

Statistical analysis
--------------------

All statistical analyses were performed with the SPSS 18.0 software (SPSS, Chicago, IL, USA). Data were presented as median and range. Pearson chi-square and Fisher's exact tests were adopted to compare the patient groups. The associations of the methylation status of the *RASSF1A* promoter with clinical parameters were assessed by Pearson's and Spearman's rank correlations. Patients were followed up for a median time of 36 months (range, 5--100 months). The Kaplan--Meier method was used to estimate survival, and differences between groups were analyzed by log-rank test. To adjust for clinical and molecular prognostic variables, a multivariate Cox model was utilized to assess the associations of survival with age, chromosomal abnormalities, *RASSF1A* methylation level, and mutation status. For all analyses, *P*\<0.05 was considered statistically significant.

Results
=======

DNA methylation status and *RASSF1A* gene expression in AML patients
--------------------------------------------------------------------

*RASSF1A* gene promoter methylation levels were assessed in BM samples from 226 AML patients and 30 healthy donors. *RASSF1A* hypermethylation was found in 23% (52/226) of AML patients, but not in healthy donors. Among the 52 patients, median *RASSF1A* hypermethylation level was 1.0279, ranging from 0.1967 to 5.336. Gene expression analysis showed significantly decreased *RASSF1A* levels in patients with *RASSF1A* hypermethylation compared with the non-methylation group ([Figure 1A](#f1-ott-10-4143){ref-type="fig"}, *P*\<0.001). Moreover, there was a significant negative association of *RASSF1A* mRNA levels with hypermethylation in both patient groups ([Figure 1B](#f1-ott-10-4143){ref-type="fig"}, *P*=0.028, *R*=−0.364).

*RASSF1A* hypermethylation is associated with chromosomal abnormalities
-----------------------------------------------------------------------

To further assess the cytogenetic abnormalities in both patient groups (with or without *RASSF1A* gene hypermethylation), various karyotypes were compared between the two groups. As shown in [Table 2](#t2-ott-10-4143){ref-type="table"}, *RASSF1A* hypermethylation was highly associated with unfavorable chromosomal abnormalities (*P*=0.049) and complex karyotype (*P*=0.016). There were no significant differences in other karyotypes between the *RASSF1A* hypermethylation and non-methylation groups.

Patients with aberrant *RASSF1A* methylation show higher *ASXL1* mutation frequencies
-------------------------------------------------------------------------------------

In the present study, *ASXL1*, *CEBPA*, *DNMT3A*, *FLT3*, *IDH1*, *KIT*, *NPM1*, *NRAS*, *RUNX1*, *SF3B1*, *SRSF2*, *U2AF1*, and *TET2* mutations were assessed in all 226 patients with non-M3 AML. The mutation spectra in both hypermethylation and non-methylation patient groups are shown in [Figure 2](#f2-ott-10-4143){ref-type="fig"}. As shown in [Table 2](#t2-ott-10-4143){ref-type="table"}, cases with aberrant *RASSF1A* methylation levels displayed a higher probability of *ASXL1* mutation (*P*=0.036). In the present work, a total of 22 patients showed *ASXL1* mutations, including 9 and 13 in the hypermethylation and non-hypermethylation groups, respectively.

Patients displaying aberrant *RASSF1A* methylation levels have adverse outcome
------------------------------------------------------------------------------

In the present study, we evaluated RFS and OS in both patient groups (with or without *RASSF1A* hypermethylation) ([Figure 3A and B](#f3-ott-10-4143){ref-type="fig"}). All 226 patients with AML were enrolled, with a median follow-up of 41 months (mean, 5--80 months). Interestingly, non-M3 AML patients with *RASSF1A* hyper-methylation exhibited reduced RFS (*P*=0.012) and OS (*P*=0.014) compared with the non-hypermethylation group. To further assess the prognostic value of *RASSF1A* methylation levels, the patients were divided into two groups according to the 75th percentile of the initial transcript levels ([Figure 3C and D](#f3-ott-10-4143){ref-type="fig"}). Consequently, 13 patients were assigned to the high methylation group, and the remaining to the low methylation group. Interestingly, patients with high *RASSF1A* methylation levels exhibited similar RFS (*P*=0.968) and OS (*P*=0.798) compared to the low methylation group.

Hypermethylation of the *RASSF1A* gene was entered into a multivariate model with variables significantly associated with prognosis in univariate analysis in the present cohort. Interestingly, *RASSF1A* hypermethylation and *U2AF1* mutation were independent prognostic factors for RFS, but not for OS ([Table 3](#t3-ott-10-4143){ref-type="table"}). Meanwhile, age ≥60 years, unfavorable karyotype, *RUNX1* mutation, *FLT3-ITD*, and *DNMT3A* mutation showed reduced RFS and OS.

Discussion
==========

Recent studies have revealed that leukemic cells exhibit various genetic and epigenetic abnormalities that contribute not only to cell transformation but also to disease progression. These novel insights not only provide clues for diagnostic stratification and prognostic evaluation but also play a key role in the appropriate selection of individuals for suitable targeted therapy.[@b23-ott-10-4143]--[@b25-ott-10-4143] DNA hypermethylation, which causes transcriptional repression, has recently emerged as one of the most frequent changes occurring in cancers, including hematopoietic tumors, and is associated with malignant transformation, making it an intriguing novel target for therapeutic targeting of leukemia.[@b26-ott-10-4143] The use of irreversible DNA methyltransferase inhibitors, including 5-azacytidine (5-aza) and decitabine, appears to be a promising option for treating myeloid malignancies, including AML.[@b27-ott-10-4143]--[@b29-ott-10-4143] *RASSF1A* is considered a candidate leukemia-suppressor gene;[@b12-ott-10-4143],[@b13-ott-10-4143] however, determining its exact effects on clinical outcome using BM samples from patients has been challenging. In addition, aberrant methylation levels of *RASSF1A* in a subpopulation of myeloid malignant patients were recently reported, but with no associations with gene mutations often detected in myeloid malignancies.[@b30-ott-10-4143] Hence, in the present study, the associations of *RASSF1A* methylation with hematological findings, cytogenetic and genetic aberrations, and clinical outcomes in AML patients were assessed.

As shown above, DNA hypermethylation of the *RASSF1A* promoter was a frequent genetic event in patients with non-M3 AML. Johan et al demonstrated that *RASSF1A* promoter methylation is found in AML and myelodys-plastic syndromes, by methylation-specific PCR.[@b31-ott-10-4143] Meanwhile, Avramouli et al found that *RASSF1AA* methylation does not frequently occur in chronic myeloid leukemia.[@b32-ott-10-4143] However, whether *RASSF1A* methylation is associated with other genetic aberrations of myeloid malignancies remains unclear. In this study, the qMS-PCR approach was employed to detect *RASSF1A* gene methylation levels. To the best of our knowledge, this is the first report assessing *RASSF1A* gene methylation levels.

Besides, *RASSF1A* methylation was evaluated in all French--American--British subtypes included in the current study, with no specific phenotype found to be highly associated. In addition, patients with aberrant methylation levels showed no decreased CR rate or one-year OS (data not shown).

In the present study, cytogenetic aberrations and gene mutations associated with hematopoietic malignancies were assessed in the *RASSF1A* hypermethylation and non-hypermethylation groups. Close associations were found of *RASSF1A* hypermethylation with unfavorable chromosomal abnormalities and complex karyotype, which are considered poor cytogenetic markers in AML.[@b16-ott-10-4143] These findings suggested that *RASSF1A* hypermethylation could be considered a novel prognostic marker for AML. However, the molecular mechanism underlying the association of *ASXL1* mutation with *RASSF1A* hypermethylation remains unknown and requires deeper fundamental research. It is worth noting that *ASXL1* gene mutations are more frequent in patients with *RASSF1A* hypermethylation. Recent studies demonstrated that *ASXL1* mutation is a reliable marker of poor outcome in AML.[@b33-ott-10-4143]--[@b35-ott-10-4143] However, such a finding was not obtained in this study, likely because only the high-frequency target sequence of *ASXL1* was detected.

We also evaluated patient survival curves in association with *RASSF1A* hypermethylation. Interestingly, patients with *RASSF1A* hypermethylation had reduced RFS compared with the non-methylation group, providing a theoretical basis for specific molecularly targeted therapy using demethylating agents.

In recent years, great progress has been made in understanding epigenetic changes in leukemia, providing a solid theoretical basis for molecular detection and diagnostic stratification, and shedding light on the development of hematologic disorders.[@b36-ott-10-4143]--[@b38-ott-10-4143] *RASSF1A* was shown to act as a leukemia-associated gene, probably playing a vital role in the occurrence of AML and other hematopoietic malignancies.

Conclusion
==========

In the current study, our analysis of *RASSF1A* promoter methylation status and its potential association with cytogenetic and molecular characteristics and clinical outcomes revealed vital points into the involvement of the *RASSF1A* gene in the pathogenesis of leukemia.

Supplementary materials
=======================

###### 

Primers and probes for detection of *MYOD1* and *RASSF1A* methylation levels

  Gene        Designation      Sequence (5′--3′) and labeling
  ----------- ---------------- -----------------------------------
  *MYOD1*     Forward primer   GTGATAAAATATTAAATGTGTTTGGTAAGTTTA
  *MYOD1*     Reverse primer   ATTTTTCTAAAAACTTCCTCAAAACTATCATC
  *MYOD1*     FAM-MGB probe    ATTGTAAAGGTAATTTGATGATAG
  *RASSF1A*   Forward primer   TGGTTTTTAGAAATACGGGTATTTTCGCGTG
  *RASSF1A*   Reverse primer   AAAACCCGAAAACGAAACTAAACGCGCT
  *RASSF1A*   FAM-MGB probe    CGTGGTGTTTTGCGGTCGTCGTCGT

###### 

Primers and probes for detection of *ABL1* and *RASSF1A* mRNA levels

  Gene        Designation      Sequence (5′--3′) and labeling
  ----------- ---------------- --------------------------------
  *ABL1*      Forward primer   AGGCTGCCCAGAGAAGGTCTA
  *ABL1*      Reverse primer   TGTTTCAAAGGCTTGGTGGAT
  *ABL1*      FAM-MGB probe    TGGAATCCCTCTGACCGG
  *RASSF1A*   Forward primer   CCTGCATGTGCTGTCACGCACAAGG
  *RASSF1A*   Reverse primer   CTCATCATCCAACAGCTTCCGCAAGTACAC
  *RASSF1A*   FAM-MGB probe    CACGTGAAGTCATTGAGGCCCTGCTG

###### 

Primers of gene mutations for sequencing

  Gene                         Primer F (5′--3′)              Primer R (5′--3′)
  ---------------------------- ------------------------------ ----------------------------
  *ASXL1*                      TGATGCTGCCTCGAGTTGTC           TTGGTCAAACCCAGCTTCTGT
  AGAAGCTGGGTTTGACCAAAGA       GTGGCTTTTCGGTGTGAACA           
  CCCCGGCTTGAAGATCGT           GTGAGTCCAACTGTAGCCCTCTGT       
  GGCACCACTTCCTGGGAAA          TGCTTCAGAGTCTCCGTTGATTT        
  GAGGCCACTAACCCACTTGTG        CCCTTGGCCTGTAACATTGC           
  *DNTM3A*                     GAAGACCCCTGGAACTGCTACA         GAAGTAGCGGGCCCTGTGT
  TCTACCGCCTCCTGCATGAT         TGGGTGCTGATACTTCTCTCCAT        
  *FLT3*                       TCCTGTTTCTCGGATGGATACC         TGGGTCATCATCTTGAGTTCTGA
  *NRAS*                       GCCGCATGACTCGTGGTT             GGCGTATTTCTCTTACCAGTGTGTAA
  *SF3B1*                      TCAACACTTAGTCCAGAAGAGCAAA      ACTTTCTGCTGCTCATCCACAA
  GCCATCTTGCCACATCTTAGAAGT     CCATCAATCAGTTGTTCTTCAAGTTT     
  TCTTCCTCCCTTTTTTAAACACTTCT   GTGGAGTCATCTTATGCATACCTATGA    
  *SRSF2*                      CGACGCTGAGGACGCTATG            AAGACCTACCCCAAATCCCATT
  *TET2*                       ATCACTCACCCATCGCATACC          TCATTGTCCCTGCAGTCTGTATGT
  ATGACATACAGACTGCAGGGACAA     TGTTGCAAAAGGTGTGAGTTTGA        
  CCAGTGTTGAAACAGCACTTGAA      GGCACAGGAAAAACATTTGCA          
  *KIT*                        TACATGGACATGAAACCTGGAGTT       AATGGTCTACCACGGGCTTCT
  *NPM1*                       AGGAGGAGGATGTGAAACTCTTAAGTAT   AACACGGTAGGGAAAGTTCTCACT
  *CEBPA*                      AAGAAGTCGGTGGACAAGAACAG        GCAGGCGGTCATTGTCACT
  *RUNX1*                      GTCATTTCCTTCGTACCCACAGT        GTGTGGGCTGACCCTCATG
  *U2AF1*                      TGTGGAGATGCAGGAACACT           AATGGCATGGCTCAGAATCG
  *IDH1*                       CCAAGTCACCAAGGATGCTG           CCATGTCGTCGATGAGCCTA
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![(**A**) Relative expression of the *RASSF1A* gene was detected in the patients with *RASSF1A* hypermethylation and the cases with non-methylation, and significant difference was found between the two groups. ^\*^Singular value. (**B**) There was a negative correlation between *RASSF1A* methylation levels and *RASSF1A* transcript levels (*R*=−0.464, *P*=0.028).](ott-10-4143Fig1){#f1-ott-10-4143}

![Spectrum of gene mutations in 226 non-M3 AML patients with hypermethylation and non-methylation of the *RASSF1A* gene.](ott-10-4143Fig2){#f2-ott-10-4143}

![(**A** and **B**) Among non-M3 AML patients, those with *RASSF1A* hypermethylation (n=52) had inferior relapse-free survival and overall survival compared to those with no hypermethylation (n=174) (*P*=0.012 and *P*=0.014, respectively). (**C** and **D**) Patients with higher *RASSF1A* methylation levels (n=13) did not show different relapse-free survival and overall survival compared to individuals with lower methylation levels (n=39) (*P*=0.968 and *P*=0.798, respectively).](ott-10-4143Fig3){#f3-ott-10-4143}

###### 

Analysis of clinical characteristics and outcome in two groups

  Variables              Total               Hypermethylation (n)   Non-methylation (n)   *P*-value
  ---------------------- ------------------- ---------------------- --------------------- -----------
  Patients (N)           226                 52                     174                   NS
  Age                    43 (12--94)         38 (14--87)            43 (12--94)           0.229
  Sex                    137 (M)/89 (F)      35 (M)/17 (F)          102 (M)/72 (F)        0.261
  M2                     54                  11                     43                    0.597
  M4                     43                  15                     32                    0.103
  M5                     60                  14                     46                    0.944
  Unclassified AML       41                  8                      33                    0.557
  WBC (×10^9^/L)         21.74 (1.9--76.3)   19.95 (1.98--76.3)     22.32 (1.9--74)       0.443
  Hemoglobin (g/L)       72 (26--131)        73 (34--131)           71 (26--126)          0.529
  Platelets (×10^9^/L)   41 (1--146)         43 (1--141)            40 (4--146)           0.414
  Marrow blasts (%)      70 (26--98)         68 (39--95)            71 (26--98)           0.179
  Induction therapy                                                                       
   IA                    70                  15                     55                    0.705
   DA                    84                  24                     60                    0.126
   MA                    72                  13                     59                    0.226
  Allo-HSCT              29                  8                      21                    0.524
  Auto-HSCT              26                  5                      21                    0.627

**Abbreviations:** NS, nonsignificant; AML, acute myeloid leukemia; WBC, white blood cell; IA, idarubicin and cytarabine; DA, daunorubicin and cytarabine; MA, mitoxantrone and cytarabine; allo-HSCT, allogeneic hematopoietic stem cell transplantation; auto-HSCT, autologous hematopoietic stem cell transplantation.

###### 

Comparison of genetic alterations between patients with acute myeloid leukemia with or without hypermethylation of the *RASSF1A* promoter

  Variant                                                                  Total (n)   Hypermethylation (n)   Non-methylation (n)   *P*-value
  ------------------------------------------------------------------------ ----------- ---------------------- --------------------- -----------
  Cytogenetic risk[a](#tfn2-ott-10-4143){ref-type="table-fn"}                                                                       
   Favorable                                                               20          4                      16                    0.955
   Intermediate                                                            151         30                     121                   0.111
   Unfavorable                                                             55          18                     37                    0.049
  Cytogenetic characteristics[b](#tfn3-ott-10-4143){ref-type="table-fn"}                                                            
   t(8;21)                                                                 12          1                      11                    0.374
   inv(16)/t(16;16)                                                        8           3                      5                     0.573
   11q23 abnormalities                                                     15          6                      9                     0.193
   Complex karyotype                                                       33          13                     20                    0.016
   Normal karyotype                                                        122         23                     99                    0.108
  Gene mutations[c](#tfn4-ott-10-4143){ref-type="table-fn"}                                                                         
   *IDH1*                                                                  23          7                      16                    0.372
   *ASXL1*                                                                 22          9                      13                    0.036
   *FLT3*                                                                  25          4                      21                    0.377
   *KIT*                                                                   8           1                      7                     0.771
   *TET2*                                                                  16          4                      12                    0.846
   *SF3B1*                                                                 9           1                      8                     0.645
   *CEBPA*                                                                 11          1                      10                    0.449
   *DNMT3A*                                                                19          7                      12                    0.225
   *NPM1*                                                                  49          10                     39                    0.625
   *NRAS*                                                                  13          2                      11                    0.739
   *SRSF2*                                                                 13          3                      10                    0.995
   *U2AF1*                                                                 18          5                      13                    0.834
   *RUNX1*                                                                 16          5                      11                    0.162

**Notes:**

Cytogenetic abnormalities were grouped according to published criteria adopted by the Southwest Oncology Group as favorable, intermediate, and unfavorable. Favorable: inv(16)/t(16;16)/del(16q), t(15;17) with/without secondary aberrations, t(8;21) lacking del(9q), or complex karyotypes; unfavorable: del(5q)/−5, del(7q)/−7, abnormalities of 3q, 9q, 11q, 20q, and 17p, t(6;9), t(9;22), and complex karyotypes; intermediate: normal karyotype and other abnormalities.

Patients may be counted more than once because of coexistence of more than one cytogenetic abnormality in the leukemic clone.

Patients may be counted more than once because of coexistence of more than one mutation in the leukemic clone.

###### 

Univariate and multivariate analysis of clinical and molecular variables for RFS and OS in non-M3 AML patients

  Variables                                                          Univariate analysis   Multivariate analysis                                                                         
  ------------------------------------------------------------------ --------------------- ----------------------- ------- ---------------------- ------- ---------------------- ------- ----------------------
  Age[a](#tfn5-ott-10-4143){ref-type="table-fn"}                     0.006                 2.730 (1.739--4.286)    0.009   2.720 (1.734--4.267)   0.002   2.540 (1.522--4.238)   0.005   2.536 (1.516--4.242)
  Unfavorable karyotype[b](#tfn6-ott-10-4143){ref-type="table-fn"}   0.041                 1.617 (1.021--2.562)    0.058   1.60 (0.985--2.473)    0.033   1.701 (1.045--2.768)   0.041   1.663 (1.022--2.706)
  *RASSF1A* hypermethylation                                         0.012                 1.782 (1.125--2.822)    0.014   1.758 (1.110--2.785)   0.040   1.622 (0.979--2.687)   0.060   1.593 (0.962--2.637)
  *ASXL1* mutation                                                   0.008                 2.238 (1.237--4.052)    0.007   2.277 (1.257--4.123)   0.058   1.863 (0.978--3.547)   0.083   1.780 (0.927--3.417)
  *FLT3-ITD*                                                         0.004                 3.009 (1.735--5.533)    0.004   3.078 (1.725--5.493)   0.021   3.518 (1.921--6.442)   0.025   3.510 (1.907--6.460)
  *RUNX1* mutation                                                   0.002                 3.278 (1.563--6.877)    0.001   3.341 (1.592--7.010)   0.005   3.078 (1.407--6.733)   0.004   3.179 (1.461--6.995)
  *DNMT3A* mutation                                                  0.006                 2.306 (1.275--4.172)    0.007   2.244 (1.241--4.058)   0.033   2.577 (1.380--4.812)   0.034   2.505 (1.340--4.684)
  *U2AF1* mutation                                                   0.011                 2.295 (1.214--4.338)    0.011   2.273 (1.203--4.295)   0.036   2.122 (1.051--4.286)   0.052   2.018 (0.994--4.097)

**Notes:**

Patients aged \>60 years vs others.

Unfavorable cytogenetics vs others.

**Abbreviations:** RFS, relapse-free survival; OS, overall survival; OR, odds ratio; CI, confidence interval.
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